Nuvonis Technologies Selected as Key Partner in Horizon Europe Initiative to Develop Next-Generation Vaccines
Nuvonis Technologies has been selected as a key consortium partner in two Horizon Europe applications focused on developing next-generation vaccines against viral pathogens with epidemic potential. The initiative aims to strengthen Europe’s preparedness for future health crises by accelerating the development and manufacturing of innovative vaccine platforms.
As the global focus shifts from pandemic response to long-term preparedness, the European Union is reinforcing its commitment to health security through Horizon Europe. The newly submitted projects are designed to address one of the most pressing challenges in modern vaccine development: the speed and scalability of vaccine production for emerging infectious diseases.
By targeting pathogens with epidemic potential, particularly viruses that could trigger future international health emergencies, the consortium seeks to establish a proactive and flexible vaccine infrastructure capable of responding rapidly to new threats.
Bridging the Gap Between Innovation and Clinical Development
The Horizon Europe initiative focuses on overcoming technical barriers that frequently delay vaccine candidates during development. By advancing innovative technologies such as viral vectors and recombinant protein platforms, the consortium aims to create a blueprint for rapid vaccine deployment.
The expected outcomes extend beyond the development of Phase 1 and Phase 2 clinical candidates. The project also seeks to establish standardized manufacturing processes and regulatory pathways that can be activated immediately when a new health threat emerges.
A central role in this effort is played by Nuvonis Technologies, an Austrian biotechnology company whose expertise and infrastructure support the transition from scientific discovery to clinical application.
Comprehensive Technical Contribution
Nuvonis contributes a broad range of capabilities across the vaccine development and manufacturing process.
- Proprietary cell lines that serve as biological production systems for high-titer vaccine manufacturing.
- Extensive regulatory expertise to support compliance with European and international pharmaceutical requirements.
- Leadership in Chemistry, Manufacturing and Controls (CMC) and Manufacturing Science and Technology (MSAT).
- Advanced process development capabilities to optimize yield, consistency and product quality.
These capabilities are intended to support a seamless pathway from vaccine concept to clinical-grade manufacturing.
Commitment to Global Health Security
According to Christina Nicolodi, Chief Executive Officer of Nuvonis Technologies, participation in the Horizon Europe projects represents both a strategic milestone and a contribution to global public health.
“Participating in these Horizon Europe projects is more than a strategic milestone for Nuvonis; it is a commitment to global health security. Our expertise in navigating the complex regulatory and manufacturing pathways of novel therapeutics allows us to bridge the gap between innovation and the clinic. At Nuvonis, we are happy to make a change in the lives of people with unmet medical needs by ensuring that the next generation of vaccines is safe, scalable, and ready when the world needs them most.”
Strategic Importance for Europe and Global Health
The participation of Nuvonis in the Horizon Europe initiative carries strategic significance on several levels.
For the European Union, the project supports the objectives of the European Health Union by strengthening vaccine development and manufacturing capabilities within Europe and reducing dependence on external supply chains during future crises.
For global health, the initiative contributes to the international “100-Day Mission”, which aims to make safe and effective vaccines available within 100 days of identifying a new pandemic threat.
For Nuvonis, participation further strengthens the company’s position within the international biotechnology ecosystem. It validates the company’s cell-bank technology, manufacturing expertise and regulatory capabilities while positioning Nuvonis as an important contributor to future medical countermeasures against emerging infectious diseases.
As the Horizon Europe projects progress, the collaboration between public funding programs and private-sector biotechnology expertise is expected to play a crucial role in strengthening preparedness for future global health threats.